title: Rat seminal vesicle protein SV-IV and its transglutaminase-synthesized polyaminated derivative SPD2-SV-IV induce cytokine release from human resting lymphocytes and monocytes in vitro.
abstract: Micromolar amounts of SV-IV, one of the major proteins secreted from the rat seminal vesicle epithelium, induce in vitro a marked release of a variety of cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin 6, and granulocyte-monocyte colony-stimulating factor) from human resting peripheral blood mononuclear cells as well as from isolated resting lymphocytes and monocytes. This effect was found to be significantly higher when the spermidine adduct of SV-IV (Spd2-SV-IV), synthesized in vitro by the enzyme transglutaminase, was used instead of the native protein. Furthermore, the pretreatment of monocytes with transglutaminase caused an increase of the inducing effect of both native and modified SV-IV on the release of interleukin 6 from these cells. The inducing effect of these proteins on the cytokine release was markedly inhibited by actinomycin D and cycloheximide.
authors.affiliation: Institute of Microbiology, Medical School, 2nd University of Naples, Italy.
authors.forename: M A
authors.initials: MA
authors.lastname: Tufano
authors.forename: R
authors.initials: R
authors.lastname: Porta
authors.forename: B
authors.initials: B
authors.lastname: Farzati
authors.forename: P
authors.initials: P
authors.lastname: Di Pierro
authors.forename: F
authors.initials: F
authors.lastname: Rossano
authors.forename: P
authors.initials: P
authors.lastname: Catalanotti
authors.forename: A
authors.initials: A
authors.lastname: Baroni
authors.forename: S
authors.initials: S
authors.lastname: Metafora
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism*; D003609:Dactinomycin / Q000494:pharmacology; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D008934:Mitogens / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D029584:Prostatic Secretory Proteins; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D029589:Seminal Plasma Proteins; D011503:Transglutaminases / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D008934:Mitogens; D029584:Prostatic Secretory Proteins; D011500:Protein Synthesis Inhibitors; D011506:Proteins; D029589:Seminal Plasma Proteins; C043076:beta-microseminoprotein; D003208:Concanavalin A; D003609:Dactinomycin; D003513:Cycloheximide; D011503:Transglutaminases